



(51) International Patent Classification:

A61K 31/165 (2006.01) A61P 19/06 (2006.01)
A61K 31/426 (2006.01) A61K 9/22 (2006.01)

(21) International Application Number:

PCT/US2014/040286

(22) International Filing Date:

30 May 2014 (30.05.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/829,759 31 May 2013 (31.05.2013) US
61/839,609 26 June 2013 (26.06.2013) US

(71) Applicants: **TAKEDA PHARMACEUTICALS U.S.A., INC.** [US/US]; One Takeda Parkway, Deerfield, Illinois 60015 (US). **TELJIN PHARMA LIMITED** [JP/JP]; 2-1, Kasumigaseki 3-chome, Chiyoda-ku, Tokyo 100-0013 (JP).

(72) Inventors: **GUNAWARDHANA, Lhanoo**; 10143 48th Avenue, Pleasant Prairie, Wisconsin 53158 (US). **GUPTE, Vijay**; 1876 Olympic Drive, Vernon Hills, Illinois 60061 (US). **NAIK, Himanshu**; 1675 Church Street, Evanston, Illinois 60201 (US). **MAYER, Michael**; 1101 Edgewater Lane, Antioch, Illinois 60002 (US). **KOMATSU, Kanji**; # 6-F, Dai 23 Miyaniwa Manshon, 2-2-2 Okubo, Shinjuku-ku, Tokyo 169-0072 (JP).

(74) Agent: **SHANER, Sandra L.**; Cantor Colburn, LLP, 20 Church St., 22nd Floor, Hartford, Connecticut 06103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: METHODS OF TREATMENT AND COMPOSITIONS WITH XANTHINE OXIDASE INHIBITORS



(57) Abstract: Methods and pharmaceutical compositions for reducing number of gout flares experienced by a patient are disclosed. The methods can comprise administering to a patient with hyperuricemia an effective amount of a xanthine oxidase inhibitor in a modified release dosage form once daily or in an immediate release dosage form two or more times daily to prevent at least one gout flare or reduce the number of gout flares experienced by the patient.



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
14 May 2015